Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of TDI01 suspension versus investigator's choice in previously treated moderate to severe chronic graft-versus-host disease
CTR20252713Phase 3Terminated
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TDI01 in chronic graft-versus-host disease (cGVHD), sponsored by Beijing Tide Pharmaceutical Co., Ltd.. Started Jul 2025; status: terminated.
02
Drugs
TDI01
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on CTR20252713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252713.